31 October 2025 - The DoH has published a revised agenda for the November 2025 PBAC meeting.

There are a few major changes. The PBAC will review new (re)submissions for:

• Desmopressin acetate (Desmomed) - new formulation
• Givosiran sodium (Givlaari) - new gene therapy
• Mirvetuximab soravtansine (Elahere) - new medicine
• Trastuzumab deruxtecan (Enhertu) - new indication

Read PBAC agenda